Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRTC 
PureTech Health PLC (PRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: PRTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $46
1 Year Target Price $46
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.28% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 425.99M USD | Price to earnings Ratio 10.37 | 1Y Target Price 46 |
Price to earnings Ratio 10.37 | 1Y Target Price 46 | ||
Volume (30-day avg) 2 | Beta 0.81 | 52 Weeks Range 13.30 - 24.99 | Updated Date 10/14/2025 |
52 Weeks Range 13.30 - 24.99 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 792.96% | Operating Margin (TTM) -2589.52% |
Management Effectiveness
Return on Assets (TTM) -12.95% | Return on Equity (TTM) 9.44% |
Valuation
Trailing PE 10.37 | Forward PE - | Enterprise Value 158046283 | Price to Sales(TTM) 66.66 |
Enterprise Value 158046283 | Price to Sales(TTM) 66.66 | ||
Enterprise Value to Revenue 25.63 | Enterprise Value to EBITDA 4.18 | Shares Outstanding 24168404 | Shares Floating 166832689 |
Shares Outstanding 24168404 | Shares Floating 166832689 | ||
Percent Insiders - | Percent Institutions 1.47 |
Upturn AI SWOT
PureTech Health PLC
Company Overview
History and Background
PureTech Health PLC is a biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases. Founded in 2005, it pioneers an approach centered around its unique R&D engine and ecosystem of Founded Entities.
Core Business Areas
- Founded Entities: PureTech identifies fundamental scientific breakthroughs and assembles dedicated teams to advance these discoveries into innovative drug candidates. These teams operate within the ecosystem of Founded Entities.
- Therapeutic Areas: Focuses on areas with significant unmet medical needs, including immunology, inflammation, rare diseases, and neurological conditions.
- Clinical Development: Manages the clinical development of its pipeline candidates, progressing them through clinical trials and regulatory submissions.
Leadership and Structure
PureTech Health PLC has a board of directors that provides oversight and strategic direction. The leadership team includes a CEO, CFO, and other senior executives responsible for managing the company's operations and strategy.
Top Products and Market Share
Key Offerings
- LYT-100 (Deupirfenidone): An oral small molecule being developed for the potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Market share is not yet established as it's in clinical development. Competitors in the IPF market include Boehringer Ingelheim (OFEV) and Roche (Esbriet).
- Vor Biopharma (VOR): Focused on engineered hematopoietic stem cells (eHSCs) for the treatment of hematological malignancies, including acute myeloid leukemia (AML). Market share is not directly applicable as it's a platform technology. Competitors include companies developing CAR-T cell therapies and other targeted therapies for AML.
- Karuna Therapeutics (KRTX)(Acquired by Bristol-Myers Squibb): Developed KarXT (xanomeline-trospium), an antipsychotic for the treatment of schizophrenia. This company was acquired, and PureTech realized a large return on investment. Competitors included companies marketing existing antipsychotics such as Johnson and Johnson (INVEGA SUSTENNA).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. It's driven by innovation and the development of new therapies for unmet medical needs.
Positioning
PureTech Health PLC is positioned as an innovator in the biotherapeutics space, focusing on early-stage drug development and creating companies around novel scientific breakthroughs. Its competitive advantage lies in its unique R&D engine and ecosystem.
Total Addressable Market (TAM)
The TAM for the therapeutic areas PureTech Health PLC targets is substantial, encompassing a multi-billion dollar market opportunity. The company aims to capture a significant share of these markets through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Unique R&D engine
- Experienced management team
- Strong network of scientific advisors
- Diverse pipeline of therapeutic candidates
- Proven track record of creating successful companies
Weaknesses
- High R&D costs
- Long development timelines
- Regulatory risks
- Dependence on successful spin-offs
- Limited commercialization experience (reliant on partners or spin-offs)
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical companies
- Acquiring promising technologies
- Capitalizing on unmet medical needs
- Advancing pipeline candidates through clinical trials
Threats
- Competition from other biopharmaceutical companies
- Failure of clinical trials
- Regulatory setbacks
- Economic downturn
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BMY
- VRTX
Competitive Landscape
PureTech Health PLC differentiates itself through its unique R&D engine and ecosystem approach. It faces competition from larger pharmaceutical companies with more established commercialization capabilities. Its advantage is in early-stage innovation and creating companies around novel science.
Major Acquisitions
Karuna Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 14000
- Strategic Rationale: Karuna was aquired by Bristol-Myers Squibb. PureTech Health realized a significant return on their investment.
Growth Trajectory and Initiatives
Historical Growth: PureTech Health PLC's growth is tied to the performance of its Founded Entities and successful exits (e.g., IPOs or acquisitions).
Future Projections: Future growth is projected to be driven by the advancement of its current pipeline candidates and the creation of new Founded Entities. Analyst estimates vary depending on the progress of its portfolio companies.
Recent Initiatives: Recent initiatives include advancing LYT-100 through clinical trials, supporting the development of its Founded Entities, and exploring new therapeutic areas.
Summary
PureTech Health PLC is a biotherapeutics company with a unique R&D model, focusing on identifying and developing innovative therapies through its ecosystem of Founded Entities. Its strength lies in its early-stage innovation and strategic partnerships. Financial performance is closely tied to the success of its portfolio companies, and regulatory risks remain a constant factor. The successful development and exit of Karuna Therapeutics is a testament to its model.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data should be verified from reputable sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PureTech Health PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-11-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.puretechhealth.com |
Full time employees 56 | Website https://www.puretechhealth.com | ||
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.